somatic mutations in mds as targets for therapy
Published 5 years ago • 106 plays • Length 2:08Download video MP4
Download video MP3
Similar videos
-
2:45
somatic mutations in mds as a diagnostic and prognostic tool
-
5:36
mds biology: somatic mutations, the microenvironment & inflammation
-
3:36
the genetic landscape of mds: how this is improving & impacting the development of therapies
-
2:34
the role of ezh2 mutations in mds
-
1:58
therapy-related mds
-
2:43
novel therapies in the future of mds treatment
-
2:07
emerging targeted treatments for mds
-
1:16
state of the art: mds
-
1:41
the role of antibody-based therapies in mds treatment
-
1:17
phase ii study of tosedostat in mds
-
6:52
somatic mutations that impact allosct outcomes in patients with aml
-
1:04
the current standard of care for mds-related cytopenias and how treatment strategies may evolve
-
1:07
an update on astral-3: guadecitabine vs treatment of choice in adults with previously treated mds
-
2:25
master final analysis: quadruplet induction therapy, asct & mrd-adapted treatment cessation in ndmm
-
1:41
using cytogenetics to improve the diagnosis and prognosis of mds & to predict response to treatment
-
3:08
welcome to the video journal of hematology & hematological oncology 🎥🩸
-
1:52
advances in lr-mds and hr-mds in 2023 and beyond
-
2:04
state-of-the-art treatment for hr-mds